RTI Surgical, Inc. (NASDAQ:RTIX) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.05-0.07 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.06. The company issued revenue guidance of $274-280 million, compared to the consensus revenue estimate of $277.84 million.

RTI Surgical (NASDAQ:RTIX) last issued its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.01 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. RTI Surgical had a negative net margin of 6.53% and a positive return on equity of 2.07%. The company had revenue of $66.69 million for the quarter, compared to the consensus estimate of $65.63 million. The company’s quarterly revenue was up .2% compared to the same quarter last year.

Several research analysts recently issued reports on RTIX shares. Zacks Investment Research downgraded shares of RTI Surgical from a hold rating to a sell rating in a research report on Thursday, October 5th. BidaskClub downgraded shares of RTI Surgical from a buy rating to a hold rating in a research report on Tuesday, August 8th.

In related news, EVP John N. Varela purchased 12,000 shares of RTI Surgical stock in a transaction that occurred on Friday, August 11th. The shares were acquired at an average price of $4.85 per share, for a total transaction of $58,200.00. Following the transaction, the executive vice president now directly owns 47,998 shares in the company, valued at $232,790.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Nicholas J. Valeriani purchased 5,500 shares of RTI Surgical stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average price of $4.70 per share, for a total transaction of $25,850.00. Following the transaction, the director now owns 47,754 shares in the company, valued at $224,443.80. The disclosure for this purchase can be found here. 4.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://theolympiareport.com/2017/11/02/rti-surgical-inc-rtix-updates-fy17-earnings-guidance.html.

About RTI Surgical

RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.

Receive News & Ratings for RTI Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.